Follow iRhythm Technologies to never miss an important update.
iRhythm reported revenue of about 224 million dollars for the quarter, a 20 percent increase over the same time last year. The company also narrowed its net loss to nearly zero, a significant improvement from the 14 million dollar loss it posted a year ago. This progress shows the business is successfully scaling its heart-monitoring platform while keeping costs under control.
Management also raised its financial goals for the full year. It now expects revenue to reach as high as 890 million dollars and adjusted EBITDA margins, a measure of cash profit before certain costs like interest and taxes, to hit 13 to 14 percent. This is a key signal for long-term owners that the company is successfully shifting from a money-losing startup into a profitable medical technology business.
See the full quarter, and how our tracked metrics did
Source: 8-K filing
iRhythm filed a notice with regulators regarding a change to its board of directors or executive leadership team. These filings are required when a company adds or loses a key leader who helps set the business strategy.
While the filing confirms a leadership shift, it does not change the company's current financial targets. For a company like iRhythm that is trying to move from high growth into steady profitability, leadership stability is important to keep its expansion into new markets on track.
Source: 8-K filing
SEC filing on 2026-08-06: 8-K, 8-K filing: entered a material agreement; reported results; Regulation FD disclosure.
Source: 8-K filing
SEC filing on 2026-08-06: 8-K, 8-K filing: entered a material agreement.
Source: 8-K filing
The company is scheduled to share its second quarter results after the market closes today. Analysts expect a loss of about 4 cents per share on revenue of roughly 220 million dollars.
Beyond the top-line numbers, the focus remains on whether the company is maintaining its pace toward full-year profitability. We are watching for updates on the rollout of its newer Zio heart monitors and any progress in clearing its outstanding warning letter from the FDA, the agency that regulates medical devices.
The company has a habit of beating analyst targets, clearing the bar in six of the last eight quarters while growing revenue by 20 percent.
| Expectation | |
|---|---|
| EPS | $0.02 |
| Revenue | $222M |
Follow iRhythm Technologies to get the latest and most important updates.
Follow IRTC